Log in to search using one of your social media accounts:

 

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

(Reuters) - The combination of Merck&Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Thoracic oncologists Drs Jack West and Hossein Borghaei talk about when to add chemotherapy to immunotherapy in high PD-L1-expressing non-small cell lung cancer patients.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy. Author: cancergrace Added: 05/11/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get a speeded-up review by U.S. regulators for use in initial treatment of people with a common form of lung cancer, the Swiss drugmaker said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Conclusions: This study showed that cPD-L1 testing is feasible, with chemotherapy influencing PD-L1 plasma levels. The possibility of using such test for predicting or monitoring the effect of immunotherapy or combination of chemotherapy and immunotherapy warrant further investigations. PMID: 29707129 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The treatment strategy in advanced non –small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as forei gn by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, a...
Source: Radiologic Clinics of North America - Category: Radiology Authors: Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Study